Similarly, in combination of mTOR and MEK inhibitors also demonstrated therapeutic advantage in treating thyroid cancer, providing further evidence that targeting both PI3K/mTOR and MAPK pathways is a potential therapeutic strategy for this disease [47], [48]. Here, MAP2K7 is linked to thyroid gland carcinoma.